

Supplementary Material

The Economic Benefit of Remission for Patients With Rheumatoid Arthritis

Jeffrey R. Curtis, MD, MS, MPH¹; Kathleen M. Fox, PhD^{2,*}; Fenglong Xie, PhD¹;
Yujie Su, MS¹; David Collier, MD²; Cassie Clinton, MSHA¹; Hafiz Oko-osi, MS, RPh³

¹University of Alabama at Birmingham, Birmingham, AL, USA

²Amgen Inc., Thousand Oaks, CA, USA

³Gilead Sciences, Inc., Foster City, CA, USA

***Corresponding author:**

Kathleen M. Fox, PhD

Amgen Inc., Thousand Oaks, CA, USA

Email: kathyfox@strategichealth.biz

Phone: +1 443-690-2198

ORCID: 0000-0003-2100-277X

Supplementary Table 1: Overall proportion of patients who change disease activity from baseline to end of follow-up


		Follow-up Stage, Patients		
		Low	Moderate	High
		Disease	Disease	Disease
	Remission	Activity	Activity	Activity
Baseline Disease				
Activity Stage, n (%)				
Remission	308 (63.5)	107 (11.1)	16 (2.5)	9 (3.5)
Low disease activity	123 (25.4)	643 (66.8)	145 (22.9)	25 (9.6)
Moderate disease activity	46 (9.5)	170 (17.7)	390 (61.7)	70 (26.9)
High disease activity	8 (1.6)	42 (4.4)	81 (12.8)	156 (60.0)

**Supplementary Table 2: Proportion of patients who change disease activity
from index to end of follow-up by RA therapy group**

	Index RA Therapy				
	csDMARDs (N = 1,219)	TNFis (N = 476)	Non-TNFis (N = 282)	tsDMARDs (N = 88)	None* (N = 274)
Stage change, n (%)					
R-R	175 (14.4)	59 (12.4)	39 (13.8)	10 (11.4)	25 (9.1)
R-L	55 (4.5)	24 (5.0)	6 (2.1)	7 (8.0)	15 (5.5)
R-M	11 (0.9)	3 (0.6)	2 (0.7)	0 (0.0)	0 (0.0)
R-H	3 (0.2)	4 (0.8)	1 (0.4)	0 (0.0)	1 (0.4)
L-R	68 (5.6)	24 (5.0)	17 (6.0)	1 (1.1)	13 (4.7)
L-L	351 (28.8)	129 (27.1)	60 (21.3)	19 (21.6)	84 (30.7)
L-M	61 (5.0)	40 (8.4)	22 (7.8)	5 (5.7)	17 (6.2)
L-H	7 (0.6)	8 (1.7)	9 (3.2)	1 (1.1)	0 (0.0)
M-R	23 (1.9)	10 (2.1)	8 (2.8)	0 (0.0)	5 (1.8)
M-L	85 (7.0)	38 (8.0)	25 (8.9)	4 (4.5)	18 (6.6)
M-M	195 (16.0)	78 (16.4)	50 (17.7)	23 (26.1)	44 (16.1)
M-H	34 (2.8)	10 (2.1)	10 (3.5)	5 (5.7)	11 (4.0)
H-R	5 (0.4)	2 (0.4)	0 (0.0)	1 (1.1)	0 (0.0)
H-L	24 (2.0)	7 (1.5)	3 (1.1)	0 (0.0)	8 (2.9)
H-M	48 (3.9)	12 (2.5)	10 (3.5)	3 (3.4)	8 (2.9)
H-H	74 (6.1)	28 (5.9)	20 (7.1)	9 (10.2)	25 (9.1)

csDMARD = conventional synthetic disease-modifying antirheumatic drug; H = high disease activity; L = low disease activity; M = moderate disease activity; R = remission; RA = rheumatoid arthritis; TNFi = tumor necrosis factor inhibitor; tsDMARD = targeted synthetic disease-modifying antirheumatic drug. *None = no DMARDs of any type in the baseline period

Supplementary Figure 1: Study design schema




Index date: The calendar date at which the patient met all inclusion/exclusion criteria and is also the date at which follow-up begins.

To be eligible, patients must have ≥ 2 rheumatologist visits with a valid CDAI measure occurring within 18 months of one another, of which one had to occur within 18 months prior to index date.

CDAI = Clinical Disease Activity Index; RA = rheumatoid arthritis; UHC = United HealthCare

Supplementary Figure 2: Mean annual costs by disease activity stage during follow-up stratified by cost type



Pharmacy total = pharmacy + intravenous infusion